Efficacy
anal cancer, anal carcinoma, thymoma, colon cancer
ADRENOCORTICAL CARCINOMA, DISEASE, THYMOMA, COLON CANCER, BEST, ANAL CANCER, ANAL CARCINOMA
Overall ORR was 3.4% (two of the 58 patients with measurable disease at baseline; 95% CI, 0.4–11.9). The DCR was 48.4% (30 of 62 patients; 95% CI, 35.5–61.4). None of the patients had confirmed (or unconfirmed) complete responses. Two patients had a confirmed partial response in the target lesions: 1 patient with thymoma in the bid 2 cohort had a duration of response of 3.7 months, and 1 patient with anal carcinoma in the qd 1.2 cohort had a duration of response of 6.9 months. The best percentage change in target lesion size was assessed for 48 patients (patients with measurable disease at baseline who had at least one post-baseline scan). The two patients with confirmed partial responses in their target lesions and one patient who had a partial response in their target lesion (but due to progressive disease in non-target lesions was evaluated as having an objective response of progressive disease) experienced a best change from baseline of approximately − 60% (Fig. 

Best change in target lesion size is defined as the maximum reduction from baseline or the minimum increase from baseline in the absence of a reduction (RECIST v1.1). Forty-eight patients, who had measurable disease at baseline and at least one post-baseline scan, were included in this analysis. The three bars on the right depict: one patient with colon cancer (bid 1) who had a partial response in the target lesion but progressive disease in non-target lesions (this patient’s objective response was evaluated as progressive disease); two patients with a confirmed partial response, one had anal cancer (qd 1.2) and the other a thymoma (bid 2)AC, adrenocortical carcinoma; ACC, adenoid cystic carcinomaStable disease was recorded in 28 (45.2%) patients (maintained for at least 8 weeks for qd 5/2 schedules, or at least 7 weeks for other schedules) and in 21 (33.9%) patients for at least 12 weeks (Table 
Response to adavosertib treatmentNone of the patients had a complete response. Overall median PFS was 2.7 months (95% CI, 2.0–3.8) (Table At the time of data cutoff (2 years and 8 months after the first patient received adavosertib treatment and 10 months after the last patient received treatment), 14 (22.6%) patients were alive and progression-free.The NGS profiles correlated to clinical outcome are summarized in Supplementary Fig. S1.